Roche signs up to $1.7bn cancer drug deal with Blueprint Medicines

Roche has entered into a licensing and collaboration agreement with Blueprint Medicines for exclusive rights to co-develop and commercialise the latter’s cancer drug, pralsetinib, outside the US, except in Greater China.

As part of the deal, Blueprint Medicines and Roche unit Genentech will co-commercialise the drug in the US.

Pralsetinib is an investigational, oral, precision therapy intended for RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), as well as other types of thyroid cancer and solid tumours.

The partners intend to expand the drug’s development in various treatment settings and explore the development of a new RET inhibitor.

Under the collaboration, Blueprint Medicines’ pralsetinib and precision therapy expertise will be combined with Roche’s global reach, personalised healthcare capabilities and cancer therapies portfolio.

Blueprint Medicines has submitted or is planning marketing applications for the drug in RET fusion-positive NSCLC, RET mutation-positive MTC and RET fusion-positive thyroid cancer in the US, Europe and other markets.

Roche expects the drug to complement its lung cancer portfolio of approved medication, including Tecentriq and Avastin while boosting its focus on driver mutations in lung cancer via personalised treatments.

Pralsetinib’s tumour-agnostic potential is also anticipated to expand Roche’s work on identifying new personalised cancer treatment approaches based on the diseases’ genetic mutation.

According to the terms of the alliance, Roche will make an upfront cash payment of $675m to Blueprint Medicines, along with a $100m equity investment in common stock. Blueprint Medicines is further eligible for up to $927m in development, regulatory and sales-based milestones, as well as sales royalties outside the US.

The companies agreed to share worldwide development expenses according to pre-specified cost-sharing percentages and equally share profits and losses in the US. Closing of the equity investment’s minority portion is contingent on the expiration or termination of the waiting period and other customary closing conditions.

Boston Scientific considers sale of speciality pharma unit

Sanofi partners with Kymera in $2bn protein degrader therapies deal

Sanofi has formed a multi-programme collaboration with biotechnology firm Kymera Therapeutics to develop and commercialise protein degrader therapies that target IRAK4 in immune-inflammatory diseases. 

Sanofi will make an upfront payment of $150m in cash to Kymera, which is eligible for additional payments of more than $2bn in potential development, regulatory and sales milestones. The partners also plan to work together on a second earlier stage programme.

Tonix to focus on precision medicine approaches for Covid-19

Tonix Pharmaceuticals has signed a research collaboration and option agreement with Columbia University to explore precision medicine approaches for vaccines and therapeutics against Covid-19.

The partners will study the immune responses to Covid-19 in healthy volunteers who recovered from the disease or were asymptomatic. The focus will be on T-cell and antibody responses at the cellular level.

Hackensack Meridian partners with Merck for Covid-19 research

The Hackensack Meridian Center for Discovery and Innovation (CDI) has entered into a research alliance with Merck to explore drugs for the treatment of Covid-19. 

As part of the research collaboration, Hackensack Meridian CDI and Merck will work to discover drug candidates that can help treat Covid-19.

Altimmune partners with DynPort on intranasal Covid-19 vaccine

Biopharmaceutical firm Altimmune has signed a teaming agreement with DynPort Vaccine to support US Government funding efforts for the development of its intranasal Covid-19 vaccine candidate, AdCOVID.

If successful, the partnership will be extended to programme management, drug development and regulatory support for the vaccine product.

Roche signs up to $1.7bn cancer drug deal with Blueprint Medicines

Roche has entered into a licensing and collaboration agreement with Blueprint Medicines for exclusive rights to co-develop and commercialise the latter’s cancer drug, pralsetinib, outside the US, except in Greater China.

As part of the deal, Blueprint Medicines and Roche unit Genentech will co-commercialise the drug in the US.